XML 57 R5.htm IDEA: XBRL DOCUMENT v3.24.0.1Close
Consolidated Balance Sheets - USD ($)
$ in Millions
Dec. 31, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 1,049.9 $ 3,419.3
Marketable securities 0.0 1,473.5
Accounts receivable, net of allowance for doubtful accounts of $2.4 and $2.3, respectively 1,664.1 1,705.0
Due from anti-CD20 therapeutic programs 435.9 431.4
Inventory 2,527.4 1,344.4
Other current assets 1,182.0 1,417.6
Total current assets 6,859.3 9,791.2
Marketable securities 0.0 705.7
Property, plant and equipment, net 3,309.7 3,298.6
Operating lease assets 420.0 403.9
Intangible assets, net 8,363.0 1,850.1
Goodwill 6,219.2 5,749.0
Deferred tax asset 928.6 1,226.4
Investments and other assets 745.0 1,529.2
Total assets 26,844.8 24,554.1 Close
Current liabilities:    
Current portion of term loan 150.0 0.0
Taxes payable 257.4 259.9
Accounts payable 403.3 491.5
Accrued expense and other 2,623.6 2,521.4
Total current liabilities 3,434.3 3,272.8
Notes payable and term loan 6,788.2 6,281.0
Deferred tax liability 641.8 334.7
Long-term operating lease liabilities 400.0 333.0
Other long-term liabilities 781.1 944.2
Total liabilities 12,045.4 11,165.7 Close
Commitments, contingencies and guarantees (Notes 22 and 23)
Biogen Inc. shareholders’ equity    
Preferred stock, par value $0.001 per share 0.0 0.0
Common stock, par value $0.0005 per share 0.1 0.1
Additional paid-in capital 302.5 73.3
Accumulated other comprehensive income (loss) (153.7) (164.9)
Retained earnings 17,627.6 16,466.5
Treasury stock, at cost; 23.8 million and 23.8 million shares, respectively (2,977.1) (2,977.1)
Total Biogen Inc. shareholders’ equity 14,799.4 13,397.9
Noncontrolling interests 0.0 (9.5)
Total equity 14,799.4 13,388.4 Close
Total liabilities and equity $ 26,844.8 $ 24,554.1